Divorced marital status was significantly associated with an increased LOS following TKA. 5 key findings →
Participants: 234 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Whole-brain bm-CVR values were significantly associated with the diagnosis group of normal, MCI, and early dementia (β = -3.00%/mm Hg, 95% confidence interval (CI) [-5.42, -0.58]), and were lower in the impaired participants relative to participants with normal cognition (β = -2.18, CI [-3.91, -0.45]). 5 key findings →
Design: cohort study Participants: 36 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Adequate assistance must be given to women caregivers to ensure that they are not strained beyond what is clinically healthy. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This article outlines methodological enhancements to better evaluate treatment approaches in future registration trials and provides an algorithm for improving the treatment of these patients in nursing home and non-nursing home settings. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The G protein Go is highly expressed in neurons and mediates effects of a group of rhodopsin-like receptors that includes the opioid, alpha2-adrenergic, M2 muscarinic, and somatostatin receptors. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ADI was significantly higher in this cohort ( M = 3.84, SD = 2.58) than in the surrounding county ( M = 2.79, SD = 1.88, p = .000). 5 key findings →
Participants: 204 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study estimated the prevalence of dementia in 2,285 new admissions age 65+ to a statewide sample of 59 nursing homes in Maryland, 1992-1995. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
44/100
Traumatic brain injury (TBI) has been linked to dementia and chronic neurodegeneration. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
(n = 14) included NH administrators and other leaders, palliative care providers, telehealth representatives, dementia advocates, a care partner, and a PLWD. 5 key findings →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Limited data suggest nursing home (NH) Alzheimer's special care units (ASCUs) may improve care and outcomes among residents with dementia. 5 key findings →
Design: cross-sectional Participants: 13,207 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
It has long been suggested that prior traumatic brain injury (TBI) increases the subsequent incidence of chronic neurodegenerative disorders, including Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Falls are common in the elderly, and frequently result in injury and disability. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
After adjusting for demographics, socioeconomics, health care access and utilization, comorbidities, and service year, we found that anti-dementia medication use was approximately 30% higher among non-Hispanic Whites compared to other racial/ethnic groups (PR=0.73, 95% confidence interval [CI]=0.59, 0.91). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
38/100
The survival of cultured mouse hippocampal neurons was found to be greatly enhanced by micromolar concentrations of the excitatory neurotransmitter glutamate. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
JOURNAL/nrgr/04.03/01300535-202606000-00056/figure1/v/2026-02-11T151048Z/r/image-tiff Cerebral small vessel disease is a major vascular contributor to cognitive impairment and dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
mice, compared with that of 5xFAD mice, a well-established AD mouse model with β-amyloid plaque pathology. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
29/100
Overall, the pathway to diagnosis (i.e., time from signs/symptoms recognition to diagnosis) ranged from 2 to 15 years. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The mechanism of action of benzodiazepines is through the modulation of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter that suppresses the central nervous system (CNS); the drugs have efficacy for short-term use (less than 1 month), but patients can develop a tolerance and dependence with long-term use.2 The benefits of benzodiazepines decrease over time and there are increased associated risks such as cognitive decline, accidental injuries, falls, and increased rates of hospital admissions and ED visits.2 Patients can also have paradoxical anxiety while on benzodiazepines.3 Studies have shown that long-term use of benzodiazepines increases the risk of dementia.4,5 Recent clinical practice guidelines recommend deprescribing benzodiazepines for older adults (age 65 years or older) for use in insomnia, and the American Geriatric Society (AGS) BEERs Criteria recommend avoidance of benzodiazepines in older adults because of the increased risk of adverse reactions such as falls and fractures.1,6 The AGS does say that benzodiazepines may be appropriate for use in older adults in certain circumstances such as ethanol withdrawal, and periprocedural anesthesia.6 The FDA has cautioned providers about prescribing benzodiazepines in patients using opioids but does not recommend withholding medications used for opioid use disorder in patients taking benzodiazepines.7,8 NPs can be instrumental in adequately treating anxiety and insomnia disorders with nonpharmacologic interventions (such as yoga and sleep hygiene) as well as with other medication classes that are not benzodiazepines. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Individuals living alone with dementia are rising rapidly, yet this group remains largely unrecognized in dementia care planning. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Neuropsychiatric symptoms (NPS) are increasingly recognized as critical components of the disease progression in Alzheimers disease (AD), yet their relationship with neurodegeneration remain poorly characterized. 2 key findings →
Participants: 1,756 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimers disease (AD) is characterized by substantial clinical and biological heterogeneity, with diverse neuroanatomical, cognitive, clinical, functional, and genetic risk profiles that are poorly captured by current diagnostic frameworks. 4 key findings →
Participants: 393 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →